Reta glucagon-like peptide-1 (GLP-1) receptor agonists offer a groundbreaking method to diabetes management. These innovative drugs function by mimicking the inherent actions of GLP-1, a hormone released by the gut in response to meals. By triggering GLP-1 receptors in the pancreas, these substances boost insulin release and inhibit glucagon output

The management of diabetes is with the emergence of exciting new therapies. Among these, Reta, GLP-1 receptor agonists, Retatrutide, and Trizepatide are gaining significant attention. These medications offer promising approaches for controlling blood sugar levels and could improve the lives of individuals living with diabetes. This novel class of